In conclusion, we found that selective inhibition of DGKα by ritanserin inhibits AML cell lines and primary patient cells both ex vivo and in in vivo mouse xenografts as a single agent in the clinically achievable range. This evidence concerns the gene DGKA and acute myeloid leukemia.